Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Neurotech USA Inc.

www.neurotechusa.com

Latest From Neurotech USA Inc.

Devices Expand Their Role in Retinal Disease

Four years following FDA approval, Lucentis remains the standard of care for the treatment of neovascular (wet) age-related macular degeneration (AMD) and has been widely adopted for off-label treatment of other retinal diseases. Companies are pursuing new drugs that may have more favorable dosing profiles, device-based technologies that may reduce the dosing frequency of Lucentis, and implantable drug delivery vehicles designed to deliver drugs to the back of the eye that may be applicable to a broad range of retinal therapies.
Medical Device

Investing in French Biotech--When It's Not Too French

Neuro 3d's €31.5 million third round late in 2004 was one of France's largest private biotech financings for years. But none of the investors are looking to France to provide the exit opportunities, which are more likely to be found in M&A, or in Switzerland.
BioPharmaceutical Business Strategies

Investing in French Biotech--When It's Not Too French

Neuro 3d's €31.5 million third round late in 2004 was one of France's largest private biotech financings for years. But none of the investors are looking to France to provide the exit opportunities, which are more likely to be found in M&A, or in Switzerland.
BioPharmaceutical Business Strategies

Transatlantic M&A: The Only Way Out for European Biotechs?

Sonus' proposed acquisition of Synt:em answers the French biotech's call for a financeable owner with upside, preferably in the US. For many European biotech firms, M&A may be their only way out of a financing hold. The Synt:em deal-granted its approved early next year--shows that it's still possible to call favorable deal terms, however.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Medical Devices
    • Implantable Devices
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Therapeutic Areas
  • Ophthalmic
  • Alias(es)
  • Neurotech SA
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Neurotech USA Inc.
  • Senior Management
  • Ted Danse, Pres. & CEO
    Richard Small, VP, CFO
    Al Reaves, PhD, VP, Clinical Dev.
    Rhett Schiffman, MD, CMO
  • Contact Info
  • Neurotech USA Inc.
    Phone: (401) 333-3880
    6 Blackstone Valley Place
    Suite 500
    Lincoln, RI 02865
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register